SeaGen Turns in FDA Application

Xconomy Seattle — 

Seattle Genetics (NASDAQ: SGEN), the developer of targeted cancer drugs, said today it has submitted an application to the FDA for clearance to start selling its first product in the U.S. The company is attempting to bring brentuximab vedotin (SGN-35) on the market as a treatment for relapsed forms of Hodgkin’s disease, and relapsed forms of anaplastic large cell lymphoma. The company has asked for a faster-than-usual six-month regulatory review, which the FDA sometimes grants for groundbreaking or potentially lifesaving therapies.